Pharmacokinetic Study of Omacetaxine Mepesuccinate Administered Subcutaneously to Patients with Advanced Solid and Hematologic Tumors.

Immune Response and Survival of Refractory Cancer Patients Who Received TGF-β2 Antisense/GM-CSF Gene Modified Autologous Tumor Cell (TAG) Vaccine.

Phase 2 Trial of Erlotinib With or Without PF-3512676 (CPG 7909, a Toll-like Receptor 9 Agonist) in Patients With Advanced Recurrent EGFR-Positive Non-Small Cell Lung Cancer.

Notch1 Activation Up-Regulates Pancreatic and Duodenal Homeobox-1.

Rao DD, Wang Z, Senzer N, Nemunaitis J: RNAi and Personalized Cancer Therapy. Discovery Medicine 2013 Feb; 15(81):101-110.

Phase 2 Trial of Erlotinib With or Without PF-3512676 (CPG 7909, a Toll-like Receptor 9 Agonist) in Patients With Advanced Recurrent EGFR-Positive Non-Small Cell Lung Cancer.

A Phase 1 Trial of Oral Ridaforolimus (AP23573; MK-8669) in Combination With Bevacizumab for Patients With Advanced Cancers.

A First-in-human, Phase 1, Dose-escalation Study of Dinaciclib, a Novel Cyclin-dependent Kinase Inhibitor, Administered Weekly in Subjects with Advanced Malignancies.

Nemunaitis J: Cancer Targeting Vaccines: Surrogate Measures of Activity. Human Vaccines & Immunotherapeutics 2013 Jan;9(1):213-218.

Bifunctional Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application (Chapter 14). In: siRNA Design: Methods and Protocols.